UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------
FORM 6-K
------------
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
The Securities Exchange Act of 1934
February 02, 2010
------------
CRUCELL NV
(Exact name of registrant as specified in its charter)
P.O. BOX 2048 ARCHIMEDESWEG 4 2333 CN LEIDEN THE NETHERLANDS
(Address of principal executive offices)
000-30962
(Commission File Number)
------------
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:
Form 20-F [X] Form 40-F [ ]
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes [ ] No [X]
CRUCELL TO RELEASE FOURTH QUARTER AND FULL YEAR 2009 RESULTS ON TUESDAY
FEBRUARY 9, 2010
LEIDEN, THE NETHERLANDS (FEBRUARY 2, 2010) - Dutch biopharmaceutical company
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced
that it will release its financial results for the fourth quarter and the full
year 2009 on Tuesday February 9, 2010 at 07:45 Central European Time (CET).
At 14:00 Central European Time (CET), Crucell's management will conduct a
conference call, which will also be webcast. To participate in the conference
call, please call one of the following telephone numbers 15 minutes prior to the
event:
+44 203 003 2666 for the UK;
+1 646 843 4608 for the US; and
+3120 794 8426 for the Netherlands
Following a presentation of the results, the lines will be opened for a question
and answer session.
The live audio webcast can be accessed via the homepage of Crucell's website at
www.crucell.com and will be archived and available for replay following the
event.
ABOUT CRUCELL
Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharmaceutical company focused on research development, production and
marketing of vaccines, proteins and antibodies that prevent and/or treat
infectious diseases. Its vaccines are sold in public and private markets
worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a
fully-liquid vaccine against five important childhood diseases and a
virosome-adjuvanted vaccine against influenza. Crucell also markets travel
vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine
and the only aluminum-free hepatitis A vaccine on the market. The Company has a
broad development pipeline, with several product candidates based on its unique
PER.C6(R) production technology. The Company licenses its PER.C6(R) technology
and other technologies to the biopharmaceutical industry. Important partners and
licensees include Johnson & Johnson, DSM Biologics, sanofi-aventis, Novartis,
Wyeth, GSK, CSL and Merck & Co. Crucell is headquartered in Leiden, the
Netherlands, with subsidiaries in Argentina, China, Italy, Korea, Spain, Sweden,
Switzerland, UK and the USA. The Company employs over 1200 people. For more
information, please visit www.crucell.com.
This press release contains forward-looking statements that involve inherent
risks and uncertainties. We have identified certain important factors that may
cause actual results to differ materially from those contained in such
forward-looking statements. For information relating to these factors please
refer to our Form 20-F, as filed with the U.S. Securities and Exchange
Commission on April 22, 2009, in the section entitled 'Risk Factors'. The
Company prepares its financial statements under International Financial
Reporting Standards (IFRS).
FINANCIAL CALENDAR
11 May 2010 Q1 Results 2010
4 June 2010 Annual General Meeting of Shareholders
17 August 2010 Q2 Results 2010
9 November 2010 Q3 Results 2010
15 February 2011 Q4 Results 2010
FOR FURTHER INFORMATION PLEASE CONTACT:
Crucell N.V.
Oya Yavuz
Vice President
Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064 ir@crucell.com www.crucell.com
SIGNATURES
Pursuant to the requirements of the Securities Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
CRUCELL NV
-----------------------------------------
(Registrant)
February 02, 2010 /s/ OYA YAVUZ
- ------------------------ -----------------------------------------
(Date) Oya Yavuz
Director of Investor Relations